Protagen AG, a specialist for GMP-compliant protein analysis and in-vitro diagnostics is presenting at the Personalized Medicine and Diagnostics Europe Congress in London. Dr. Stefan Müllner, CEO of Protagen AG will discuss the latest achievements in personalized medicine together with an expert panel of representatives from pharma, biotech and diagnostic. Protagen AG has developed the proprietary UNIarray® technology platform to develop product specific companion diagnostics and patient stratification tools for clinical studies. Indication specific autoantibody patterns are not only present in classical autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals. Therefore, the systematic profiling of autoantibodies will serve as a unique basis to address the needs of the personalized medicine market.
Protagen and all other key players in personalized medicine will be discussing real solutions to the industry’s challenges at the Personalised Medicine & Diagnostics Europe conference in London on the 9th and 10th of March. You are cordially invited to meet us and join the presentation of Dr. Stefan Müllner, CEO, on March 9th entitled „Using autoantibodies in companion diagnostics“. For further information please refer to http://www.eyeforpharma.com/personalizedmedicine/
About Protagen AG
Protagen AG (www.protagen.de) is an international leading specialist in the fields of in-vitro diagnostics and GMP-compliant protein analysis. The innovations of Protagen are UNIarray®, a technology platform for the development of novel serum based diagnostics, as well as UNIchip®, a versatile product family of protein microarrays for faster development of antibodies.
Contact
Dr. Stefan Müllner
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: info@protagen.de
Media Enquiries
Bettina Franz
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail: bettina.franz@protagen.de
